Utilization of invariant natural killer T cells for gastric cancer treatment

Future Oncol. 2018 Aug;14(20):2053-2066. doi: 10.2217/fon-2017-0724. Epub 2018 Jul 27.

Abstract

Aim: To evaluate the expression of CD1d and the susceptibility to invariant natural killer T (iNKT) cells in gastric cancer.

Methods: The expression of CD1d was examined in gastric cancer. The in vitro and in vivo cytotoxic activities of iNKT cells were evaluated against gastric cancer cell lines.

Results: CD1d was expressed in gastric cancer cell lines and primary tumors. iNKT cells have potent in vivo and in vitro anti-tumor activities against CD1d-positve gastric cancer in the presence of α-galactosylceramide. Cisplatin could upregulate CD1d expression in gastric cancer cells and make them more vulnerable to iNKT cell-mediated cytotoxicity.

Conclusion: These results justified clinical translation of this iNKT cell-based therapeutics, either used alone or combined with chemotherapy, for the treatment of patients with gastric cancer.

Keywords: CD1d; gastric cancer; invariant natural killer T cells.

MeSH terms

  • Animals
  • Antigens, CD1d / metabolism
  • Biomarkers
  • Cell Line
  • Cell- and Tissue-Based Therapy
  • Cisplatin / pharmacology
  • Combined Modality Therapy
  • Cytokines / metabolism
  • Cytotoxicity, Immunologic
  • Disease Models, Animal
  • Flow Cytometry
  • Humans
  • Immunotherapy
  • Mice
  • Mice, Inbred NOD
  • Natural Killer T-Cells / drug effects
  • Natural Killer T-Cells / immunology*
  • Natural Killer T-Cells / metabolism
  • Stomach Neoplasms / immunology*
  • Stomach Neoplasms / therapy*
  • Xenograft Model Antitumor Assays

Substances

  • Antigens, CD1d
  • Biomarkers
  • CD1D protein, human
  • Cytokines
  • Cisplatin